Human protein C (Baxalta)

N/A

Report date: 2026/01/19 09:18:49

Base Information

Drug NameHuman protein C (Baxalta)
Drug Alias NameProtein CHuman protein C (Hyland Immuno)Protein C Concentrate (Human, Hyland Immuno)CeprotinTAK-662
ClassificationBiologics > Blood components
Mechanisms of ActionProtein C replacementsCoagulation factor VIII inhibitorsFactor Va inhibitors
TargetsCoagulation factor VCoagulation factor VIII
Therapy Area/IndicationsPurpura FulminansProtein C DeficiencyVenous Thromboembolism
Global Approved IndicationsPurpura FulminansProtein C DeficiencyVenous Thromboembolism
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2001/07/15
Country/TerritoryUnited StatesEUJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBaxalta Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Manufacturing Austria AgTakeda Pharmaceutical Co Ltd
Inactive CompaniesBaxalta Incorporated
Active IndicationsPurpura FulminansProtein C DeficiencyVenous Thromboembolism
Inactive IndicationsN/A

Other Information

ATC CodeB01AD12
Related LinksN/A